Pharnext

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40
Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Pharnext

Bericht door And its gone! »

Gaan we dit morgen verderzetten? :shock: :lol:
PHARNEXT (ALPHA)
ISIN: FR0011191287

LAATSTE
(26/03/20 - 17:36)
4,81
WIJZIGING
(1,11)
30,00%
BID
4,8
ASK
4,84
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.



besportie
Forum veteraan
Forum veteraan
Berichten: 1166
Lid geworden op: 13 feb 2012 18:07
waarderingen: 302
Contacteer:

Re: Pharnext

Bericht door besportie »

Volgende week een update:

PARIS, France, le 7 Avril 2020 à 17h40 (CET) - Pharnext SA (FR0011191287 - ALPHA), une société biopharmaceutique pionnière d'une nouvelle approche pour développer des combinaisons de médicaments innovantes basées sur les grandes données génomiques et l'intelligence artificielle, annonce aujourd'hui l'organisation d'une réunion d'information à destination de l'ensemble de ses actionnaires le jeudi 23 avril 2020, à 18h (CET).
A cette occasion, Daniel Cohen MD, PhD, co-fondateur et Directeur Général de Pharnext, fera par Webcast un point d'avancement sur la Société, le développement clinique et la recherche.

Les inscriptions sont ouvertes à l'adresse suivante : https://channel.royalcast.com/pharnext/ ... 20200423_3

Bron: Boursorama
Turbo long Galapagos, Argen-x, Fugro / Turbo short Dow Jones / aandelen: Soligenix 3.47$, Sorrento 2.50$, Euronav 8.97€ / cash

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Pharnext

Bericht door And its gone! »

PHARNEXT (ALPHA)
ISIN: FR0011191287

LAATSTE
(14/04/20 - 09:13)
4,92
WIJZIGING
(0,86)
21,18%
BID
-
ASK
-
Het is weer de ene freeze na de andere...
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

step by step
Forum verkenner
Forum verkenner
Berichten: 19
Lid geworden op: 18 jun 2018 09:54
waarderingen: 12
Contacteer:

Re: Pharnext

Bericht door step by step »

And its gone! liked last!

BeursWim
Forum newbie
Forum newbie
Berichten: 1
Lid geworden op: 17 apr 2020 09:09
waarderingen: 0
Contacteer:

Re: Pharnext

Bericht door BeursWim »

Hai daar,

Zeker twee belangrijke mededelingen. Is iemand bekend met de staat van dienst van nieuwe CEO?

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Pharnext

Bericht door And its gone! »

BRIEF-Pharnext Announces Partnership To Evaluate Drugs For Potential Use Against COVID-19
08:23 (22/04) - Bron: Reuters
April 22 (Reuters) - Pharnext SA :
* PHARNEXT AND THE UNIVERSITY HOSPITAL INSTITUTE
MÉDITERRANÉE
INFECTION ANNOUNCE A JOINT EFFORT TO EVALUATE REPURPOSED DRUGS
FOR POTENTIAL USE AGAINST THE COVID-19 VIRUS
* JOINT ACTIVITIES WILL FOCUS ON RAPIDLY TESTING ALREADY
APPROVED
DRUGS THAT WERE PREVIOUSLY IDENTIFIED AS POTENTIAL CANDIDATES
FOR FIGHTING COVID-19
* TESTING WILL BE PERFORMED BY UHI MÉDITERRANÉE INFECTION IN
PRECLINICAL STUDIES AND WILL BUILD UPON GROUNDBREAKING WORK OF
THIS INSTITUTE

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

step by step
Forum verkenner
Forum verkenner
Berichten: 19
Lid geworden op: 18 jun 2018 09:54
waarderingen: 12
Contacteer:

Re: Pharnext

Bericht door step by step »

Mooie stappen vind ik het tot nu toe van de onderneming, er wordt duidelijk gewerkt.
Uitkijkend naar morgen naar de webcast om alles eens mooi op een rijtje te zien voorbijkomen.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Pharnext

Bericht door And its gone! »

Pharnext Reports Financial Results for Year-End 2019
PARIS, France, 19:00 pm, April 22, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), an advanced clinicalstage biopharmaceutical company pioneering a new approach to developing innovative drug combinations
based on big genomic data and artificial intelligence, today announced its financial results for the fiscal year
ended December 31, 2019.

2019 KEY EVENTS
In January 2019, Pharnext raised €15.0 million in capital from longstanding shareholder CBLUX. This additional
cash inflow will give Pharnext more resources to focus, in particular, on the development of PXT3003. Under
a series of agreements entered into with Tasly on May 10, 2017, the Chinese pharmaceutical group subscribed
for €25.0 million in convertible bonds, which, according to the terms of the agreement, have been fully
converted within the first quarter 2019 into common shares.

In the end of August 2019, Pharnext completed its discussions with the FDA concerning the positive results of
its pivotal Phase 3 PLEO-CMT study, previously announced in October 2018, in which the high dose arm was
prematurely stopped due to an unexpected intercurrent formulation event. Because of this intercurrent event,
the FDA advised that Pharnext run an additional Phase 3 study to ultimately support a New Drug Application
for PXT3003 in CMT1A. The FDA acknowledged that CMT1A is a disease with high unmet medical need,
granting Fast Track designation for PXT3003 in February 2019, and encouraged Pharnext to return to discuss a
proposed study design.
In November 2019, Pharnext established an equity line facility to enhance the Company’s financial flexibility
and improve liquidity for shareholders. Kepler Cheuvreux committed to underwrite up to 3,000,000 shares.
SYNTHETIC FINANCIAL INFORMATION
The key financial items for the fiscal year 2019 are set out in the table below. These data were taken from the
financial statements drawn up under IFRS, which were approved by the Board of Directors at its meeting on
April 22, 2020. The financial statements were duly audited and the auditors’ report on the certification of the
financial statements is in the process of being issued. The full financial statements are available on the
Pharnext website: www.pharnext.com
Income Statement items (in €k) under IFRS at Dec. 31 2019 2018
Income from ordinary operations 253 2,687
Other income 3,345 4,142
Administrative costs -8,445 -7,072
Research and development costs -15,178 -17,665
Operating income (expense) -20,025 -17,908
Financial income (expense) -3,284 -3,409
Net income (expense) -23,309 -21,317
Net cash flows generated by operating activities -21,568 -15,911
Net cash flows generated by investing activities 194 -402
Net cash flows generated by financing activities 14,860 26,619
PHARNEXT | CREATING NEW SOLUTIONS
Page 2
Net change in cash and cash equivalents -6,515 10,307
Cash and cash equivalents 16,247 22,761
Other income mainly consists of the Research Tax Credit (€3.2 million for 2019) and subsidies.
Decreasing in Research & Development costs are mainly explained by the decrease of clinical costs due to the
timing of the testing phases associated with PXT3003 for CMT1A.
Financial charges amounted to €2 million, mainly due to the interest amounts relating the bonds subscribed
by IPF, as notes subscribed by Tasly have been converted within 2019 and interest costs from OSEO DIPPAL
are quite the same.
As a result, Pharnext posted a net loss of €23.3 million in 2019.
Balance Sheet items (in €k) under IFRS at Dec. 31 2019 2018
Cash 16,247 22,761
Borrowings and financial debt 23,403 47,623
In terms of balance sheet structure, the net change in cash within 2019 year ended decreased by -€6.5 million
and financial debt decreased by €26 million due to the conversion into shares the amount of Tasly notes,
including principal and Interest. Cash and cash equivalents amounted to €16.2 million at December 31, 2019
versus 22.8 million at year-end 2018.
RECENT ACTIVITIES
Financial transactions
In March 2020, Pharnext raised €7.7 million in capital from longstanding shareholders CBLUX and LOHAS and
from new US shareholders. This additional cash inflow will give Pharnext additional resources to focus on the
additional Phase 3 clinical study of PXT3003.
As of the date of this press release, Pharnext collected a total proceeds of € 4,828,692 from the equity line
executed by Kepler Cheuvreux since March 31.
These funding have boosted Pharnext’s capital, these transactions raised Pharnext’s cash position to € 22.1
million at the date of release of this document.
Given the difficulties of holding meetings due to the coronavirus pandemic, Pharnext's Board of directors
decided to postpone the annual shareholders' meeting to a future day within next July . Pharnext will announce
a new date for this annual shareholders' meeting in due course.
Scientific and management development
In March 2020, United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) has granted
Promising Innovative Medicine (PIM) designation to Pharnext lead drug candidate, PXT3003, for the treatment
of Charcot-Marie-Tooth Disease Type 1A (CMT1A) in patients 16 years and older. A PIM designation is an early
indication that a medicinal product is a promising candidate for the Early Access to Medicines Scheme (EAMS)
in the treatment, diagnosis or prevention of life-threatening or seriously debilitating conditions with unmet
need.
In March 2020, Pharnext has identified, through the use of its PLEOTHERAPYtm platform, 97 frequently
prescribed drugs as potential candidates to be repositioned for treating COVID-19.
PHARNEXT | CREATING NEW SOLUTIONS
Page 3
Pharnext has announced on April 16, 2020 the appointment by its board of Dr. David Horn Solomon as Chief
Executive Officer. Pr. Daniel Cohen, who co-founded Pharnext in 2007, will assume the position of Chairman
of the Scientific Advisory Board.
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Pharnext

Bericht door And its gone! »

step by step schreef:
22 apr 2020 08:49
Mooie stappen vind ik het tot nu toe van de onderneming, er wordt duidelijk gewerkt.
Uitkijkend naar morgen naar de webcast om alles eens mooi op een rijtje te zien voorbijkomen.
Zal dan toch een kort rijtje zijn.

3 jaar verloren met hun fase 3 studie, en nu meer schulden dan cash.
Die alzheimer studie zijn ze gewoon vergeten :D

Het enige wat ze hebben is hun AI platform, waar na een passage van Galapagos geen kat meer in geïnteresseerd lijkt.
Ze blijven wel Galapagos nog gebruiken in hun actuele presentaties wat ik persoonlijk lichtelijk misleidend vind.


Ik wacht nog even tot deze boven mijn gemiddelde van 6.5€ stijgen (wat vroeg of laat zal gebeuren) en dan gaan mijn Pharnexts bijna zeker op de schop. Ik ga waarschijnlijk die nieuwe fase 3 studie niet meer afwachten, het moest maar weer eens mislukken (zie Asit, etc). Dan spreken we trouwens al van 2022.
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Pharnext

Bericht door And its gone! »

De nieuwe CEO heeft zijn entree niet gemist.
Webcast gisteren was blijkbaar teleurstellend met niks van nieuws, vandaar de koersreactie vandaag.

Ik zal nog even moeten wachten om deze zonder verlies kwijt te raken :roll:
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen.


Plaats reactie